Friday, April 21, 2023
Description
BAP1-TPDS is a relatively new cancer predisposition syndrome first reported by Drs. Abdel-Rahman, Davidorf and Cebulla in 2011. BAP1-TPDS is a multi-cancer syndrome associated with predisposition to several cancers. The professional practice gap is the knowledge deficit of the diagnosis and management of subjects and families with disease causing variants in the BAP1 gene. Several cancers have been reported in patients with germline BAP1 mutations. The gaps in knowledge includes which cancers should the patients be followed up for, the frequency of the follow up, and the types. Also, recent advances in the research and targeted therapies for BAP1 will be discussed.
For pricing information, see pricing tab below.
Dates and Times
Start: 4/21/2023 8:00 AM
End: 4/21/2023 12:30 PM
Objectives
At the conclusion of this activity, learners will be able to:
1. Recognize the role of genetic testing when treating patients diagnoses with BAP1 gene mutation.
2. Identify other types of cancers that are associated with BAP1 gene mutation.
3. Apply emerging research to patient care when treating BAP1 gene mutation diagnosis.
4. Identify resources and educational opportunities for BAP1 gene mutation patients.
Agenda
AGENDA (CME)
Friday, April 21, 2023
Conference Room 3000
7:30 a.m. REGISTRATION AND CONTINENTAL BREAKFAST
8:00 a.m. Welcoming Remarks:
Colleen Cebulla, MD, PhD
Associate Professor
Vice Chair for Research, Department of Ophthalmology and Visual Sciences
8:05 a.m. Title: BAP1-Tumor Predisposition Syndrome current knowledge and challenges
Speaker: Mohamed Abdel-Rahman, MD, PhD
Ophthalmology and Cancer Genetics, The Ohio State University Medical Center
8:25 a.m. Title: European Guidelines for diagnosis and management of BAP1-TPDS
Helen Hanson, MD
Cancer Genetics, St George’s, University Hospital NHS Foundation Trust, UK
8:45 a.m. Title: BAP1 Syndrome: Lessons from Genetically Engineered Mouse Models
Speaker: Joseph Testa, PhD
Pathology, Fox Chase Cancer Center
9:05 a.m. Title: BAP1 and Uveal Melanoma
Speaker: Colleen M. Cebulla, MD, PhD
Ocular Oncology, The Ohio State University Medical Center
9:25 a.m. Title: Incidence, diagnosis, and management of BAP1-Inactivated Melanocytic Cutaneous Tumors
Speaker: Arnaud de la Fouchardière, MD
Département de Biopathologie, Centre Léon Bérard, France
9:45 a.m. Audience Question & Answer Session
10:00 a.m. BREAK
10:15 a.m. Title: BAP1 Targeted therapies, update on clinical trials and medicolegal aspects
Speaker: Muaiad Kittaneh, MD, MBA-HCM, FACP
Medical Oncology, ICON plc
10:35 a.m. Title: Updates in managements of mesothelioma in BAP1-TPDS patients
Speaker: David Schrump, MD
Thoracic Oncology, NCI
10:55 a.m. Title: BAP1 and renal carcinoma, diagnosis, and management
Speaker: Maria Carlo, MD
Medical Oncology and Genetics, MSKCC
11:15 a.m. Title: BAP1 genetic counseling challenges and future directions
Speaker: Lindsey Byrne, CGC
Division of Human Genetics, The Ohio State University Medical Center
11:35 a.m. Title: BAP1 and sex cord stromal tumors of the ovary
Speaker: Christa Nagel, MD
Gynecologic Oncology, The Ohio State University Medical Center
11:50 a.m. Title: BAP1 and meningioma. When to suspect BAP1-TPDS
Speaker: Joshua Palmer, MD
Radiation Oncology, The Ohio State University Medical Center
12:05 p.m. Surgical management of atypical meningioma
Kyle Wu, MD
Neurosurgery, The Ohio State University Medical Center
12:15 p.m. Audience Question & Answer Session
12:30 p.m. Meeting Evaluation
Lunch Break
ATTENDEES ADJOURNED FOR THE DAY
Pricing
| Tier | Price |
|---|---|
| In-Person | $60.00 |
| Virtual Learner | $40.00 |
Speakers
Location
Ohio State Havener Eye Institute Eye and Ear Institute AND VIRTUAL
915 Olentangy River Rd
Conference Room 3000
Columbus, OH 43215
Accreditation
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.